A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients


Rello J., Krenn C., Locker G., Pilger E., Madl C., Balica L., ...Daha Fazla

CRITICAL CARE, cilt.21, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

Background: Currently, no vaccine against Pseudomonas is available. IC43 is a new, recombinant, protein (OprF/I)-based vaccine against the opportunistic pathogen, Pseudomonas aeruginosa, a major cause of serious hospital-acquired infections. IC43 has proven immunogenicity and tolerability in healthy volunteers, patients with burns, and patients with chronic lung diseases. In order to assess the immunogenicity and safety of IC43 in patients who are most at risk of acquiring Pseudomonas infections, it was evaluated in mechanically ventilated ICU patients.